Non‐alcoholic fatty liver disease is associated with cardiovascular disease risk markers
Key result
Non-alcoholic fatty liver disease is associated with an increased cardiovascular disease risk profile, though well-designed randomized clinical trials and long-term follow-up studies are scarce.
Why the study?
Does treatment of non-alcoholic fatty liver disease improve cardiovascular disease risk profile?
Population
Patients with non-alcoholic fatty liver disease (NAFLD)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
NAFLD signals elevated CVD risk warranting attention; leaves open whether treatment modifies outcomes.
Structured PICO
Does treatment of non-alcoholic fatty liver disease improve cardiovascular disease risk profile?
P
Population
Patients with non-alcoholic fatty liver disease (NAFLD)
E
Exposure
Diet, laparoscopic surgery, and pharmacological approaches
O
Outcome
Cardiovascular disease (CVD) risk profile and hepatic fat content
This review highlights the association between NAFLD and increased cardiovascular risk, emphasizing the potential benefits of lifestyle and surgical interventions on CVD risk markers.
Limitations
- Effects of pharmacological approaches are often confounded by weight change.
- Well-designed intervention studies, randomized clinical trials and long-term follow-up studies are scarce.
- Scarcity of well-designed intervention studies, randomized clinical trials, and long-term follow-up studies
- Pharmacological effects are often confounded by weight change
Cite This Study
Edens et al. (2009) conducted a review in Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Non-alcoholic fatty liver disease (NAFLD) was evaluated. Non-alcoholic fatty liver disease is associated with an increased cardiovascular disease risk profile, though well-designed randomized clinical trials and long-term follow-up studies are scarce.